Israel Innovation Authority

Eretz Angels supports technology startups in Israel's outskirts at the start of their journey.

IR-MED LTD. is a medical device company based in Rosh Pinna, Israel, specializing in infrared light-based diagnostic systems. Founded in 2012, the company leverages advanced technologies, including big data and machine learning, to create innovative diagnostic modalities. IR-MED develops continuous and real-time monitoring devices capable of detecting and measuring various substances and pharmaceuticals in the blood. Additionally, their systems can assess fluid concentrations on surfaces and behind thin tissues, facilitating the identification and characterization of medical lesions and pathological processes in humans.

BloomX is an AI pollination solution for crops in which pollination is a limiting factor for their yield. The company allows growers to increase their revenue by enlarging yields in existing crops and improving fruit quality. BloomX's vision is to provide an AI-based pollination solution that addresses each crop’s pollination needs by mimicking the natural pollination process and enhancing it using technology. Bumblebee was founded in 2019 and is headquartered in Tel Aviv, Israel.

BioBetter is a foodtech company based in Israel, established in 2015. It specializes in developing plant-based platforms for the production of complex growth factors essential for cultivated meat. The company leverages agri-tech innovations to simplify the manufacturing and purification processes of proteins, particularly focusing on the use of transgenic plants as bioreactors. By co-expressing therapeutic proteins with enzymes that eliminate antigenic sugars, BioBetter enhances the efficiency of protein expression, enabling biotech professionals to significantly reduce production costs.

SuperMeat is an Israeli bio-tech and food-tech company based in Tel Aviv, founded in 2015. It specializes in producing cultured meat from chicken cells in a sterile and controlled environment, eliminating the need for antibiotics and reducing the risk of contamination from pathogens such as salmonella. The company aims to revolutionize the meat industry by providing a sustainable alternative to traditional poultry farming, significantly decreasing resource requirements—99% less land and 90% less water—while offering a product that maintains a rich flavor and aroma. SuperMeat's innovative approach aspires to enhance nutritional security and reduce carbon emissions, contributing to a healthier future for both humans and animals.

VALFIX Medical, established in 2016 and based in Tel Aviv, Israel, specializes in the design and development of transcatheter solutions for Mitral and Tricuspid valve repair and replacement. The company's innovative, minimally-invasive approach combines repair and replacement treatments, providing a viable alternative to open-heart surgery. Utilizing its proprietary multi-wire technology, VALFIX aims to alleviate heart failure symptoms and treat various heart-related conditions by addressing mitral regurgitation.

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.

BeeHero is a company that specializes in beehive technology aimed at enhancing crop yields through efficient pollination. Founded in 2017 by Itai Kanot, Omer Davidi, and Yuval Regev, the company leverages artificial intelligence and machine learning, utilizing low-cost sensors to gather data from within beehives. This innovative approach helps stimulate optimal bee productivity during critical pollination periods, thereby assisting farmers in safeguarding their beehives against colony collapse and improving overall pollination effectiveness. With operations based in Tel Aviv and Silicon Valley, BeeHero employs a team of 50 individuals, with a significant portion dedicated to research and development in its Israeli center.

ViAqua Therapeutics Ltd is an innovative biotechnology company based in Misgav, Israel, focused on developing therapeutics for the aquaculture industry. Founded in 2014, ViAqua is pioneering an orally administered particle-based platform that aims to prevent viral epidemics affecting aquatic species. The company utilizes a proprietary RNAi nanoparticle formulation that activates a cellular response to disable viral infections. This technology enables the delivery of coated nanoparticles through feed or immersion, significantly enhancing the resistance of shrimp and other aquaculture species to viral diseases. With a management team possessing extensive experience in business development and industrial biotechnology, ViAqua Therapeutics is positioned to make a substantial impact on the health and sustainability of aquaculture practices.

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.

FertilAI is a healthcare company focused on enhancing fertility treatment success rates through innovative technologies. Based in Israel, the company leverages advanced AI algorithms to automate and optimize clinical decision-making for physicians during fertility treatments. Its flagship platform, Fertilane, enables seamless communication among clinics, doctors, and patients through specialized doctor/patient applications and administrative web applications designed for fertility workflows. Founded by a team of technology experts and leading reproductive endocrinologists, FertilAI aims to elevate the overall patient experience in fertility care while supporting clinics in their operational scalability.

Phytolon Ltd is a company based in Misgav, Israel, specializing in the development of natural food colorants. Founded in 2000, Phytolon utilizes a novel fermentation technology that employs baker's yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach offers a healthy alternative to synthetic food dyes, providing food manufacturers with safe, cost-effective, and stable all-natural color solutions. The company's mission is to leverage scientific advancements to promote human health and environmental sustainability in the food industry.

Vessi Medical is an Israeli medical device startup focused on innovating treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC) through a novel surface cryotherapy approach. This technique employs extreme cold to freeze and eliminate abnormal tissue, providing a minimally invasive alternative to the standard TransUrethral Resection of Bladder Tumor (TURBT), which is often inadequate and requires invasive surgery under general anesthesia. Vessi's technology, comprising a standalone console and a disposable catheter, allows for targeted cell destruction while safeguarding healthy bladder tissue. This office-based procedure not only reduces the need for costly hospital stays and repeat surgeries but also addresses the high recurrence rate of NMIBC, which affects millions globally. With promising proof of concept already demonstrated in animal studies, Vessi aims to capture the $1.2 billion NMIBC market, while also exploring future applications for treating overactive bladder and urinary tract infections. The company is supported by experienced professionals in the medical device and cryotherapy sectors, ensuring a strong foundation for its innovations.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. The company specializes in enhancing endoscopic procedures through advanced technologies such as artificial intelligence, deep learning, and computer vision. Its flagship product is the Automatic Polyp Detection System (APDS), which aids physicians during colonoscopy by automatically identifying suspicious polyp locations in real-time or in offline mode on pre-recorded videos. This innovation is designed to improve the accuracy of polyp detection, thereby reducing the miss-rate associated with colonoscopies, which can lead to interval cancer. Given the high volume of colonoscopy procedures performed annually, Magentiq Eye's solutions aim to enhance diagnostic effectiveness, ultimately contributing to better patient outcomes and significant healthcare cost savings. The APDS can be integrated with existing colonoscopy systems or offered as a service to clinics and hospitals, positioning Magentiq Eye as a key player in the medical device industry focused on improving endoscopic practices.

90 days from launch (Dec 20): - 4 paying clients in 90 days, 25 days sales cycle. - 10,000 users covering all 10 largest cities of Israel. Together with our SafeUPer we - Create a Safe World for Women - One community at a time. Create – We believe people must take an action, getting out of our comfort zone, to achieve this change. Sharing stories is simply not enough. Safe – We believe being safe is a basic right of all women, and like all women right achieved by previous generations, it will be gained with sweat and tears. World – We are facing a global problem, documented for at least two millennia (2,000 yrs), maybe the only problem impacting women daily, of all ages, countries, backgrounds and beliefs. Therefore. We believe it should be solved globally, empowering women all around the world to bring safety to their local communities. Women – We believe that when women will have peace, men too will have peace. Men have proven that they are unable to bring peace and safety by themselves to themselves nor to women. Therefore, we need to lead and bring it together.

DiA Imaging Analysis Ltd. is a technology company based in Beersheba, Israel, specializing in AI-powered ultrasound analysis designed to enhance the evaluation of cardiac function and other medical conditions. Founded in 2009, DiA offers a range of innovative applications, including LVivo EF for automated ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain, which assesses myocardial strain as an early indicator of reduced left ventricular function. Their tools simplify the ultrasound imaging process by providing automated analysis and optimal view selection, improving the diagnostic capabilities of clinicians. DiA's technology is compatible with various ultrasound devices and healthcare IT systems, streamlining the detection of clinical abnormalities. The company holds FDA and CE clearances and serves thousands of users globally, addressing critical challenges in ultrasound utilization by enabling more accurate and efficient image analysis through advanced pattern recognition and machine learning algorithms.

XRHealth Ltd. is a medical technology company based in Tel Aviv, Israel, that specializes in developing virtual reality (VR) software solutions for healthcare. Founded in 2016, the company offers an array of products designed to enhance patient care and treatment outcomes. Its offerings include VRPhysio, a platform for virtual physical therapy; VRReliever, which helps manage pain through distraction; VRCogni, aimed at improving motor function in stroke and dementia patients; and VRPsyc, which provides exposure therapy for various mental health disorders. Additionally, VRCoordi is designed to aid coordination recovery in patients with Parkinson's, brain injuries, and autism. By integrating immersive technologies with licensed clinicians and advanced data analytics, XRHealth provides comprehensive telehealth services, allowing patients to access treatment from the comfort of their own homes.

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.

AgroScout Ltd. is an Israeli company established in 2017 that specializes in developing an artificial intelligence-based platform aimed at enhancing sustainable farming practices. The company's technology provides precision agriculture solutions by utilizing advanced analytics and high-resolution aerial imagery to assess crop health and monitor for pests and diseases. AgroScout's platform supports farmers by offering insights on crop emergence, stand counts, canopy coverage, and biomass throughout the growing season. This continuous monitoring allows for early detection of infestations, enabling more effective curative treatments and reducing pesticide use. By delivering actionable insights into crop management and regional outbreak predictions, AgroScout aims to improve crop yields and profitability while fostering a more sustainable food production supply chain.

Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an innovative AI-powered patrol drone tailored for indoor security and inspection tasks. The drone employs independent AI navigation and a patented unobtrusive ceiling docking system, providing real-time monitoring and predictive analysis to minimize false alarms. Tando's automated data collection and analysis capabilities ensure consistent quality, enhancing safety and security measures. By integrating robotics with advanced AI, Indoor Robotics aims to deliver efficient and cost-effective solutions for intelligent indoor monitoring. Collaborating with leaders in the security and smart building sectors, the company is at the forefront of transforming indoor surveillance and inspection through cutting-edge technology.

Yemoja Ltd. is a marine biotech company based in Upper Galilee, Israel, established in 2017. The company specializes in the sustainable production of high-value ingredients derived from microalgae for the cosmetic, food, and pharmaceutical industries. Yemoja offers a range of products, including DSkin, an extract from dunaliella salina; Algae Glow, derived from porphyridium cruentum; and EPS Glow, which features porphyridium polysaccharides. Additionally, the company produces various bioactive compounds such as astaxanthin, polysaccharides, xanthophylls, carotenoids, and enzymes with antioxidant properties. Yemoja employs state-of-the-art technology and patented processes to achieve high yields and quality standards, and it is currently expanding its production capacity by constructing a new facility designed to meet Good Manufacturing Practices (GMP).

Greeneye Technology is an innovative company based in Tel-Aviv, Israel, focused on transforming agricultural pest control through advanced technology. Established in 2017, Greeneye has developed a proprietary selective spraying system that employs artificial intelligence and machine learning to enable real-time detection of weeds, allowing for precise and targeted herbicide application. This approach significantly reduces herbicide usage by up to 90%, minimizing waste and promoting sustainable farming practices. The company boasts a multidisciplinary team with expertise in areas such as computer vision, agronomy, and mechanical engineering, all dedicated to providing effective and environmentally friendly solutions for farmers worldwide.

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, CathWorks aims to transform coronary angiography from subjective visual assessments into an objective decision-making tool. The company's flagship product, CathWorks FFRangio, is a non-invasive device that provides multi-vessel physiologic measurements, allowing physicians to optimize and confirm PCI therapy decisions during procedures. By leveraging functional flow reserve (FFR) data and automated algorithms, CathWorks enhances the use of coronary angiography data, promoting measurement-based medicine and improving operational efficiency in cath labs.

RenalSense Ltd. is a medical device company specializing in innovative solutions for real-time renal diagnostics. Founded in 2009 and headquartered in Jerusalem, Israel, with an additional office in Brookline, Massachusetts, the company has developed Clarity RMS, a critical care monitoring system that continuously measures urine flow. This system automatically transmits real-time data to medical staff and alerts them to fluctuations, facilitating early detection of changes in renal function and the risk of acute kidney injury (AKI). RenalSense addresses a significant gap in the healthcare industry, as existing products primarily report kidney damage only after it occurs. By focusing on early detection and prevention, RenalSense aims to improve patient outcomes and reduce healthcare costs, setting new clinical standards in the management of AKI patients in critical care environments.

Soapy Care Ltd, founded in 2017 and based in Tel Aviv, Israel, specializes in manufacturing IoT-powered hygiene micro-stations. These innovative devices are designed to dispense precise doses of soap and water, enhancing hand hygiene compliance in various settings. The company offers proprietary smart soap capsules that ensure accurate dosing, thereby addressing significant challenges related to healthcare-associated infections and regulatory compliance. Soapy Care's products are commercially active in markets including India and the United States, where they have received numerous awards for their groundbreaking impact. The company aims to transform hand-washing practices into measurable data, benefiting various stakeholders while providing a cost-effective and reliable sanitation solution.

Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases. Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusive technology lowers the extra BCAA that is floating around.

Convizit Ltd. is a company based in Tel Aviv, Israel, that specializes in web analytics software designed to track and analyze user interactions on websites and SaaS applications. The company's innovative platform employs artificial intelligence to automatically capture user events, enriching this data with relevant properties and delivering it seamlessly to various analytics and marketing platforms. By eliminating the need for manual coding and tagging of user interactions, Convizit allows businesses to access comprehensive and reliable behavioral data with minimal effort. This approach not only simplifies the data collection process but also enhances the utility of the information gathered, enabling website owners and SaaS vendors to leverage behavioral insights for analytics, marketing, and personalization. Convizit is actively expanding its team of developers, engineers, and data scientists to continue disrupting traditional methods of behavioral data collection and utilization.

DiA Imaging Analysis Ltd. is a technology company based in Beersheba, Israel, specializing in AI-powered ultrasound analysis designed to enhance the evaluation of cardiac function and other medical conditions. Founded in 2009, DiA offers a range of innovative applications, including LVivo EF for automated ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain, which assesses myocardial strain as an early indicator of reduced left ventricular function. Their tools simplify the ultrasound imaging process by providing automated analysis and optimal view selection, improving the diagnostic capabilities of clinicians. DiA's technology is compatible with various ultrasound devices and healthcare IT systems, streamlining the detection of clinical abnormalities. The company holds FDA and CE clearances and serves thousands of users globally, addressing critical challenges in ultrasound utilization by enabling more accurate and efficient image analysis through advanced pattern recognition and machine learning algorithms.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. The company specializes in enhancing endoscopic procedures through advanced technologies such as artificial intelligence, deep learning, and computer vision. Its flagship product is the Automatic Polyp Detection System (APDS), which aids physicians during colonoscopy by automatically identifying suspicious polyp locations in real-time or in offline mode on pre-recorded videos. This innovation is designed to improve the accuracy of polyp detection, thereby reducing the miss-rate associated with colonoscopies, which can lead to interval cancer. Given the high volume of colonoscopy procedures performed annually, Magentiq Eye's solutions aim to enhance diagnostic effectiveness, ultimately contributing to better patient outcomes and significant healthcare cost savings. The APDS can be integrated with existing colonoscopy systems or offered as a service to clinics and hospitals, positioning Magentiq Eye as a key player in the medical device industry focused on improving endoscopic practices.

MedAware Ltd is a company focused on enhancing patient safety and reducing healthcare costs through innovative solutions that detect and eliminate prescription errors. Established in 2012 and based in Raanana, Israel, MedAware employs advanced data analytics and machine learning algorithms to analyze extensive electronic medical records. Its key products include the MedAS alerting system, which provides real-time notifications to prevent prescription errors, as well as decision support tools such as MedRIM for risk management, MedQC for quality control, and MedRAF to reduce alert fatigue. By offering these solutions to healthcare providers, pharmacy benefit management companies, and pharmacy chains, MedAware aims to improve the accuracy of prescriptions and mitigate potential risks associated with drug interactions, dosages, and allergies.

Phytolon Ltd is a company based in Misgav, Israel, specializing in the development of natural food colorants. Founded in 2000, Phytolon utilizes a novel fermentation technology that employs baker's yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach offers a healthy alternative to synthetic food dyes, providing food manufacturers with safe, cost-effective, and stable all-natural color solutions. The company's mission is to leverage scientific advancements to promote human health and environmental sustainability in the food industry.

Talenya Ltd is a technology-driven company that specializes in talent sourcing solutions. Founded in 2016 and headquartered in Rosh Haayin, Israel, with an additional office in Hoboken, New Jersey, Talenya utilizes artificial intelligence and machine learning to streamline the recruitment process. Its platform employs advanced algorithms to identify potential candidates by collecting and analyzing data from various online sources. This enables the platform to match candidate profiles with job openings effectively. Talenya's solution not only automates the talent sourcing process but also assesses and validates leads, presenting employers with qualified and diverse candidates. By empowering talent experts to establish their own recruitment practices, Talenya facilitates immediate access to both employers and suitable candidates.

SoftWheel is a technology company based in Tel Aviv, Israel, that specializes in developing advanced in-wheel suspension systems. Founded in 2011, the company focuses on enhancing personal mobility by creating innovative suspension solutions for wheelchairs, bicycles, and automobiles. SoftWheel's products include suspension arms and wheel rims, which are designed to absorb shocks and vibrations while providing rigidity and stability. The company operates through a network of resellers both domestically in Israel and internationally. It has established strategic partnerships with leading global companies such as NSK and Linamar to drive sustainable transportation and improve people’s lives through innovative technology.

Yarok Microbio is a company that specializes in advanced microbiological testing technology for the agriculture and food supply sectors. It has developed a system that significantly accelerates the detection of harmful microbes, including E. coli, Listeria, and Salmonella, providing results in just 45 minutes compared to the days required by traditional methods. This rapid testing capability addresses critical needs in the AgriFood industry, helping producers avoid costly product recalls, lawsuits, and ensuring consumer safety. The technology is versatile, applicable across various food categories, and also offers early detection of plant pathogens, which aids in the timely implementation of phytosanitary measures and reduces pesticide use. Yarok's research and development laboratory is based in Jerusalem, Israel, with a demonstration lab in Milan, Italy, to support marketing efforts in Europe. The company has received recognition for its innovative approach, including the UNIDO Innovation Award in 2017 and being named one of the Top Five Disruptors in the food technology sector by the Institute of Food Technologists in 2019.

ElastiMed Ltd. is a medical device company specializing in innovative compression therapy solutions. Founded in 2015 and based in M.P. Misgav, Israel, ElastiMed develops wearable devices that utilize advanced smart materials to enhance circulation in the legs. Their flagship product, a smart compression sock, employs proprietary technology to compress and massage the legs in response to electrical stimulation. This device is aimed at treating chronic venous insufficiency and preventing conditions such as deep vein thrombosis, swelling, and leg ulcers. ElastiMed's solutions offer patients a comfortable, effective, and affordable treatment option, catering particularly to the needs of elderly individuals suffering from venous and lymphatic diseases.

Augmedics is a company that develops augmented reality-guided surgical systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2014, the company is headquartered in Yoqneam Ilit, Israel, with an additional office located in Chicago, Illinois. Its flagship product, the xvision-spine (XVS) system, features a head-mounted display that allows surgeons to visualize the patient's anatomy through skin and tissue, significantly improving their ability to navigate during complex surgeries. The system integrates real-time positioning of surgical tools and utilizes illumination to enhance the focus area, providing critical insights and assistance to surgeons throughout the procedure. Augmedics strives to revolutionize surgical treatment by leveraging advanced technology to improve healthcare delivery.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

AbiliSense Ltd., established in 2015 and headquartered in Tel Aviv-Yafo, Israel, specializes in developing sound recognition technology. The company's core product enables IoT devices to continuously monitor environmental sounds, providing real-time alerts for potential hazards or anomalies to applications, emergency call-centers, or smart devices. This innovation aims to enhance safety and security by empowering IoT devices with AI-driven smart listening capabilities.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Nanofabrica is a pioneering company based in Tel Aviv, Israel, specializing in 3D printing technology for precision manufacturing. Founded in 2016, the company focuses on micro and nanomanufacturing, offering solutions for various sectors, including semiconductors, optics, and medical devices. Its innovative Micro Adaptive Projection technology enables the production of ultra-precise and complex parts with an unprecedented micron-resolution. This capability allows for rapid manufacturing of high-performance components, significantly reducing costs and time compared to traditional methods. By integrating advanced optics and semiconductor lithography with 3D printing, Nanofabrica serves mass customization needs, responding to customer feedback to continuously refine its technology and expand into new markets such as robotics and biomedical applications.

Atomation is a company specializing in Internet of Things (IoT) solutions, providing software and hardware development kits to facilitate the creation of smart objects. Founded in 2014 and headquartered in St. Louis, Missouri, with additional locations in Tel Aviv, Israel, and Philadelphia, Pennsylvania, Atomation focuses on connecting existing, in-field legacy objects and assets to the internet. The company's platform serves sectors such as agriculture, medical, industrial, and logistics, enabling clients to gather data from various devices, including home automation systems, medical equipment, and industrial machinery. By transforming sensor data into actionable information, Atomation allows businesses to optimize operations and make informed real-time decisions, ultimately enhancing their efficiency and profitability.

Catalyst AgTech Ltd. is an Israeli company focused on developing innovative technology for the agriculture sector, specifically aimed at minimizing the environmental impact of agrochemical products. The company has created a customizable technology with a self-destruction mechanism designed for use in persistent pesticides, herbicides, and fungicides. This patented catalyst technology effectively breaks down specific chemicals in fertilizers, significantly reducing their harmful effects after application and preventing groundwater contamination. By addressing the growing demand for essential pesticides while mitigating adverse environmental consequences, Catalyst AgTech offers a solution that promotes sustainable agricultural practices. The company is supported by an experienced management team and benefits from scientific collaboration with the Weizmann Institute of Science.

IR-MED LTD. is a medical device company based in Rosh Pinna, Israel, specializing in infrared light-based diagnostic systems. Founded in 2012, the company leverages advanced technologies, including big data and machine learning, to create innovative diagnostic modalities. IR-MED develops continuous and real-time monitoring devices capable of detecting and measuring various substances and pharmaceuticals in the blood. Additionally, their systems can assess fluid concentrations on surfaces and behind thin tissues, facilitating the identification and characterization of medical lesions and pathological processes in humans.